Recent studies proved that targeting ANXA1 abrogated Treg-mediated immune suppression in triple-negative breast cancer, and ANXA1 was considered a worse prognostic and TME marker in gliomas (Bai et al., 2020; Lin et al., 2021). The gene discussed is ANXA1; the disease is glioma.